Sucampo Pharmaceuticals (SCMP +6.6%) climbs higher after Cantor Fitzgerald says excitement surrounding the opioid-induced constipation drug Amitiza "could significantly rally the stock" in the short-term. Additionally, the company's partnership with Takeda (TKPHF.PK +3.4%) makes for a compelling long-term story. SCMP is initiated at Buy with a $9 price target.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs